Intravitreal Bevacizumab for Age-Related Macular Degeneration
- Sponsor
- Asociación para Evitar la Ceguera en México
- Study ID
- NCT00347165
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Age Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
Study Details
The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration
Key Dates
- First listed
- Jul 4, 2006
- Start date
- Sep 30, 2005
- Status verified
- May 2024
- Primary completion
- Jun 30, 2006
- Completion
- Sep 30, 2006
Study Design
- Enrollment
- 50 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Improvement of visual acuity at 6 months
Related Studies
- Strategies for Improving Linkage-to-Care After Eye Disease ScreeningRecruiting · University of California, San Francisco · San Francisco, California
- Phase 1 Study of C.001 in Retinal DegenerationPHASE1 · Recruiting · Cellio Therapeutics Inc · Beverly Hills, California